M1-receptor–selective drugs could be designed to promote receptor signaling via phosphorylation/arrestin-dependent pathways, thereby not only delivering symptomatic relief in AD, by improving memory and reducing anxiety, but also delivering neuroprotection that will maintain normal behavior and extend life span. This evidence concerns the gene SAG and Alzheimer disease.